Blog
About

16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors.

      Anticancer research

      therapeutic use, Humans, Intestinal Neoplasms, radiotherapy, Lung Neoplasms, Middle Aged, Neoplasms, Unknown Primary, Neuroendocrine Tumors, Octreotide, adverse effects, analogs & derivatives, Palliative Care, Pancreatic Neoplasms, Prospective Studies, Radiopharmaceuticals, Yttrium Radioisotopes

      Read this article at

      ScienceOpenPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The aim of this study was to assess the efficacy and safety of targeted radionuclide therapy with [90Y-DOTA0, Tyr3]-octreotide (90Y-DOTATOC) in patients with metastatic neuroendocrine tumors. One hundred and sixteen patients with metastatic neuroendocrine tumors were included. All patients were pre-therapeutically staged with morphological imaging procedures and with somatostatin receptor scintigraphy. The scintigraphy was positive in all cases. The patients were treated with 162-200 mCi/m2 body surface. In 57 patients, the quality of life was assessed with the National Cancer Institute grading criteria (NCI-CTC). Restaging was performed 8-12 weeks after the last treatment cycle. Blood samples were drawn every 2 weeks after the treatment to evaluate toxicity. Complete remissions were found in 4%, partial remissions in 23%, stabilization in 62% and progressive disease in 11%. A significant reduction of symptoms was found in 83%. No serious adverse event occurred and the toxicity was acceptable. 90Y-DOTATOC is a safe and effective treatment for patients with metastatic neuroendocrine tumors.

          Related collections

          Author and article information

          Journal
          16739341

          Comments

          Comment on this article